BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 23, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2011

View Archived Issues

Sanofi-aventis presents highlights of first quarter of 2011

Read More

Novel tetracycline TP-2758 efficacious in models of urinary tract infections and pyelonephritis

Read More

New nicotinic acetylcholine alpha7 receptor agonists claimed

Read More

Novel agents for Gram-negative bacterial infections synthesized at Pfizer

Read More

Merck & Co. patents new inhibitors of Mdm2-p53 interaction

Read More

Cephalon begins phase I/II CEP-9722 trial in advanced solid tumors

Read More

Albany Medical School and Aegis Therapeutics join to develop peptide against breast cancer

Read More

Evotec achieves new milestone in Boehringer Ingelheim drug discovery alliance

Read More

AstraZeneca discloses preclinical data on AZD-5363, in phase I testing in solid tumors

Read More

VT-1129 shows benefit in model of cryptococcal meningitis

Read More

Pooled trial data show linaclotide improves symptoms of constipation

Read More

AZD-2066 reduces transient lower esophageal sphincter relaxations in healthy subjects

Read More

Concert Pharmaceuticals prepares new GABA(A) receptor modulators

Read More

New sepiapterin reductase inhibitors claimed

Read More

Pharmacyclics discloses new tyrosine-protein kinase BTK inhibitors

Read More

Gentium submits defibrotide MAA to EMA for hepatic VOD in stem cell transplant recipients

Read More

Phase III trial of istradefylline in Parkinson's disease meets primary endpoint

Read More

Roche seeks FDA and EMA approval for vemurafenib in metastatic melanoma

Read More

National Cancer Institute to sponsor phase I study of Reolysin in multiple myeloma

Read More

Results from Asian study of lurasidone in schizophrenia inadequate to support filing in Japan

Read More

Sosei gains Japanese rights to antifungal agent Loramyc from BioAlliance

Read More

Allos Therapeutics and Mundipharma to codevelop anticancer drug Folotyn

Read More

Takeda acquires exclusive rights to fomepizole in Japan from Paladin Labs

Read More

Swissmedic approves Novartis' Votubia for brain tumors associated with tuberous sclerosis

Read More

Galapagos commences second proof-of-mechanism phase I trial of GLPG-0778

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 22, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing